ASCO Annual Meeting | Conference

Trastuzumab Deruxtecan Prolongs PFS in Pretreated HR+, HER2-Low and -Ultralow Metastatic Breast Cancer

June 2nd 2024

Trastuzumab deruxtecan improved PFS vs chemotherapy in pretreated, HR-positive, HER2-low or -ultralow metastatic breast cancer.

Zanidatamab Shows Durable Responses With Longer Follow-up in Pretreated HER2+ Biliary Tract Cancer

June 2nd 2024

Zanidatamab continued to show confirmed responses, disease control, and prolonged overall survival in pretreated HER2+ biliary tract cancer.

Cabazitaxel/Abiraterone Combination Prolongs PFS vs Abiraterone in mCRPC

June 2nd 2024

Cabazitaxel plus abiraterone acetate and prednisone improved PSA response and extended PFS vs abiraterone acetate and prednisone in patients with mCRPC.

Pembrolizumab Plus Sacituzumab Govitecan Shows Nonsignificant Trend Toward Improved PFS in HR+ Breast Cancer

June 2nd 2024

Pembrolizumab plus sacituzumab govitecan numerically improved PFS vs the ADC alone in HR-positive, HER2-negative metastatic breast cancer.

Virtual and In-Person Delivery of Palliative Care Confers Equivalent QOL Benefit in Advanced Lung Cancer

June 2nd 2024

The delivery of palliative care through telehealth vs in-person visits was equally beneficial for patients with advanced non–small cell lung cancer.

Lymphadenectomy Fails to Boost Survival in Advanced Ovarian Cancer

June 2nd 2024

The addition of lymphadenectomy to cytoreductive surgery did not improve progression-free or overall survival in advanced ovarian cancer.

Consolidation Durvalumab to Become New SOC for LS-SCLC After Chemoradiation

June 2nd 2024

Consolidation treatment with durvalumab after concurrent chemoradiation led to a survival benefit vs placebo in limited-stage small cell lung cancer.

Osimertinib Could Alter SOC for Stage III EGFR+ NSCLC

June 2nd 2024

Osimertinib after definitive chemoradiotherapy improved PFS vs placebo in locally advanced, EGFR-mutated non–small cell lung cancer.

Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer

June 2nd 2024

Perioperative chemotherapy with FLOT improved OS vs neoadjuvant chemoradiation with CROSS in resectable esophageal cancer.

Neoadjuvant Nivolumab/Ipilimumab New Standard of Care for Stage III Melanoma

June 2nd 2024

Neoadjuvant nivolumab/ipilimumab followed by TLND and response-driven adjuvant therapy reduced the risk of progression, recurrence, or death in melanoma.

Belantamab Mafodotin Plus Pd Elicits PFS Benefit in R/R Myeloma

June 2nd 2024

Belantamab mafodotin plus BPd improved PFS vs PVd in relapsed/refractory multiple myeloma.

Tucidinostat Plus R-CHOP Improves EFS in DLBCL Expressing MYC and BCL2

June 2nd 2024

Tucidinostat plus R-CHOP improved efficacy and was safe in previously untreated DLBCL expressing MYC and BCL2.

Abemaciclib/Fulvestrant Boosts PFS in HR+/HER2– Breast Cancer Post–CDK4/6i Progression

June 2nd 2024

Abemaciclib plus fulvestrant improved PFS vs fulvestrant alone in select patients with hormone receptor–positive/HER2-negative advanced breast cancer.

Inavolisib Plus Palbociclib/Fulvestrant Bolsters PFS in HR+/HER2–, PIK3CA-Mutant Breast Cancer

June 1st 2024

Inavolisib plus palbociclib and fulvestrant reduced the risk of progression or death in HR+/HER2– PIK3CA-mutated advanced or metastatic breast cancer.

Dr Cho on Amivantamab Plus Lazertinib in Atypical EGFR-Mutated NSCLC

June 1st 2024

Byoung Chol Cho, MD, PhD, discusses findings from the CHRYSALIS-2 trial of amivantamab plus lazertinib in patients with atypical EGFR-mutant NSCLC.

Dr Freedland on Treatment Suspension and HRQoL During the EMBARK Trial in nmHSPC

June 1st 2024

Stephen J. Freedland, MD, discusses the correlation between treatment suspension and HRQoL in patients with nmHSPC who were enrolled on the phase 3 EMBARK trial.

Anthracycline Plus Chemo Associated With Improved RFS in MP High-2–Risk, HR+/HER2– Early Breast Cancer

June 1st 2024

Anthracycline/taxane/cyclophosphamide was linked to improved RFS in MammaPrint high-2–risk, BluePrint Luminal B, HR-positive, HER2-negative breast cancer.

Adagrasib Improves Survival, Responses in KRAS G12C+ Advanced NSCLC

June 1st 2024

Compared with standard-of-care chemotherapy, adagrasib significantly improved PFS and tumor responses in KRASG12C-mutated locally advanced or metastatic NSCLC.

DFF332 Elicits Efficacy and Is Safe in Advanced Clear Cell RCC

June 1st 2024

The small molecule inhibitor DFF332 elicited clinical activity and had a tolerable safety profile in patients with advanced clear cell renal cell carcinoma.

Neoadjuvant Sacituzumab Govitecan Displays Activity in Muscle-Invasive Bladder Cancer, But Questions Remain

June 1st 2024

Neoadjuvant sacituzumab govitecan demonstrated efficacy in patients with muscle-invasive bladder cancer, but its future role in the space is uncertain.

x